

blood

2002 100: 718-720
Prepublished online Apr 17, 2002;
doi:10.1182/blood-2002-01-0209

Transcobalamin II 775G>C polymorphism and indices of vitamin B12 status in healthy older adults

Joshua W. Miller, Marisa I. Ramos, Marjorie G. Garrod, Margaret A. Flynn and Ralph Green

Updated information and services can be found at:

<http://bloodjournal.hematologylibrary.org/cgi/content/full/100/2/718>

Articles on similar topics may be found in the following *Blood* collections:

[Red Cells](#) (1173 articles)

[Brief Reports](#) (1234 articles)

Information about reproducing this article in parts or in its entirety may be found online at:

http://bloodjournal.hematologylibrary.org/misc/rights.dtl#repub_requests

Information about ordering reprints may be found online at:

<http://bloodjournal.hematologylibrary.org/misc/rights.dtl#reprints>

Information about subscriptions and ASH membership may be found online at:

<http://bloodjournal.hematologylibrary.org/subscriptions/index.dtl>



Brief report

Transcobalamin II 775G>C polymorphism and indices of vitamin B12 status in healthy older adults

Joshua W. Miller, Marisa I. Ramos, Marjorie G. Garrod, Margaret A. Flynn, and Ralph Green

A common polymorphism (775G>C) in the vitamin B12 transport protein, transcobalamin II (TCII), has been identified in which proline replaces arginine at codon 259. We determined the influence of TCII genotype on indices of B12 status, including total serum B12, the amount of B12 bound to TCII (holoTCII), methylmalonic acid, and homocysteine, in 128 healthy older adults (ages 40-88 years). Mean

total B12 and homocysteine concentrations were not significantly different among the 3 genotypes. Mean holoTCII concentration was significantly higher in those subjects homozygous for the proline form of TCII (PP) compared with those homozygous for the arginine form (RR) and heterozygotes (PR) ($P \leq .006$). In addition, mean methylmalonic acid concentrations were significantly lower in the

PP and PR groups compared with the RR group ($P \leq .02$). The PP genotype may be more efficient in delivering B12 to tissues, resulting in enhanced B12 functional status. TCII genotype may thus influence susceptibility to B12 deficiency. (Blood. 2002;100:718-720)

© 2002 by The American Society of Hematology

Introduction

The serum protein, transcobalamin II (TCII), transports vitamin B12 (B12) from the ileum to the tissues. The B12-TCII complex (holoTCII) is then taken up into cells by receptor-mediated endocytosis. In the 1970s and 1980s, 2 research groups independently identified distinct isopeptide forms of TCII by polyacrylamide gel electrophoresis^{1,2} and isoelectric focusing.³ More recently, DNA sequencing has revealed that the isopeptide forms of TCII are the result of single nucleotide polymorphisms.⁴⁻⁶ The most common polymorphism in white populations is a G-to-C substitution at base position 775 (775G>C), which results in the replacement of proline with arginine at codon 259. Recently, the potential influence of the 775G>C polymorphism on indices of vitamin B12 status has been investigated. Persons homozygous for the proline form of the protein (PP) tend to have higher holoTCII but similar total serum B12 concentrations compared with those homozygous for the arginine form (RR).⁷⁻¹¹ One group has found that homocysteine, a functional indicator of B12 status, is higher in heterozygous persons (PR) than in PP and RR persons,^{8,11} but this finding was not confirmed.^{9,10} Notably, the relationship between TCII genotype and methylmalonic acid, potentially a more specific indicator of B12 status than homocysteine, has not been reported. Therefore, we assessed the relationship between 775G>C TCII genotype and methylmalonic acid and between total B12, holoTCII, and homocysteine in a cohort of healthy older adults.

Study design

Subjects

The study sample consisted of 108 men and 20 women (mean age, 67 years; range, 40-88 years). Subjects are current participants in the Longitudinal

Aging Study, initiated in 1969 and continuing through the present at the University of Missouri-Columbia.¹² The study population consisted primarily of University of Missouri faculty and staff who were physically active and in apparent good health, with no evidence of decreased intrinsic factor secretion or gastrointestinal B12 malabsorption. The project was approved by the University of Missouri-Columbia Institutional Review Board and all participants provided their informed consent.

TCII genotyping

Polymerase chain reaction (PCR) product was amplified using an Eppendorf Mastercycler (Brinkmann, Westbury, NY) in a total reaction volume of 25.0 μ L containing 7.0 μ L genomic DNA, 1.5 mM MgCl₂, 0.2 mM dNTP mix, 2.0 μ M forward primer (5'-GTC-AGG-TGC-TGG-AAC-ACC-TAG-3'), 2.0 μ M reverse primer (5'-CGT-TCT-GAA-CCA-CAA-GAC-CTA-3'), 2.5 μ L 10 \times PCR buffer, and 1 U Taq polymerase (Gibco BRL/Life Technologies, Rockville, MD). The amplification consisted of initial denaturation (94°C, 2 minutes); 35 cycles consisting of denaturation (94°C, 1 minute), annealing (64°C, 1 minute), and extension (72°C, 2 minutes); and final extension (72°C, 7 minutes). PCR product was digested at 37°C overnight in a total reaction volume of 20 μ L containing 15 μ L PCR product, 2 μ L 10 \times digestion buffer, and 20 U *Mva*I restriction enzyme (Roche Molecular Biochemicals, Indianapolis, IN). Digested samples were electrophoresed on 1% agarose and 2% NuSieve GTG (FMC Bioproducts, Rockland, ME) gels and were visualized (Figure 1) using the NucleoVision Gel Documentation System (NucleoTech Corporation, San Mateo, CA).

Metabolite assays

Fasting serum B12 and RBC folate were determined by automated chemiluminescence assay (ACS180; Bayer Diagnostics, Tarrytown, NY); methylmalonic acid by gas chromatography-mass spectrometry¹³; homocysteine by high-performance liquid chromatography with fluorescence detection¹⁴; creatinine by standard spectrophotometric assay; and holoTCII by indirect assay using anti-TCII antibodies¹⁵ as follows: activated Sepharose beads were coupled with polyclonal antibody raised in goats inoculated

From the Departments of Medical Pathology and Nutrition, School of Medicine, University of California, Davis, and the Department of Family and Community Medicine, School of Medicine, University of Missouri, Columbia.

Submitted January 25, 2002; accepted March 9, 2002. Prepublished online as *Blood* First Edition Paper, April 17, 2002; DOI 10.1182/blood-2002-01-0209.

Supported by the Wallace Research Fund, Cedar Rapids, IA; the Eshe Fund, New York, NY; and the School of Medicine, University of Missouri, Columbia.

Reprints: Joshua W. Miller, Department of Medical Pathology, Medical Center, Research III, Room 3200A, 4645 Second Ave, University of California-Davis, Sacramento, CA 95817; e-mail: jwmiller@ucdavis.edu.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.

© 2002 by The American Society of Hematology

with rabbit TCII purified by photo-dissociative affinity chromatography.¹⁶ The antibody shows immunologic cross-reactivity with human holoTCII.¹⁷ In the assay, goat anti-rabbit TCII antibody-coated Sepharose beads were washed and resuspended as a 5% mixture in phosphate-buffered saline. One-milliliter aliquots of the washed beads were transferred to microfuge tubes and centrifuged at 3000g (5 minutes). After aspiration of the supernatant, serum samples (500 μ L) were added to the bead pellet, mixed for 2 hours at room temperature, and centrifuged at 3000g (5 minutes). B12 concentrations were determined in the supernatants by radioassay (Simult-rac Radioassay; ICN Pharmaceuticals, Orangeburg, NY). The difference in B12 concentration between untreated serum and bead-treated serum represented the holoTCII level. In this assay, antibody-coated beads consistently remove more than 98% of ⁵⁷Co-cyanocobalamin-labeled holoTCII (data not shown). Mean (\pm SD) for holoTCII in 22 nondeficient, healthy volunteers was 104.1 (\pm 66.7) pg/mL (range, 38-305 pg/mL). Within and between assay coefficients of variation in nondeficient samples were 15% and 17%, respectively.

Statistical analyses

Mean (\pm SD) for each metabolite was compared by analysis of variance, controlling for age, sex, and other covariates as indicated, followed by Scheffé F-test.

Results and discussion

Characteristics of the study sample divided by TCII genotype are presented in Table 1. The distribution of genotypes among the subjects was 30% PP, 50% PR, and 20% RR, similar to previous reports.⁷⁻¹⁰ No differences among the genotypes were observed for hematocrit and MCV, and no subjects had evidence of macrocytic anemia. The mean holoTCII concentration was significantly higher in the PP subjects than in the PR and RR subjects, but no differences in mean total B12 were observed. These results are consistent with previous reports.⁷⁻¹¹ The mean methylmalonic acid concentration was significantly higher in the RR subjects than in the PP and PR subjects. Taken together, these findings suggest that TCII genotype influences the cellular delivery of B12 and directly impacts 1 of the 2 biochemical reactions in which B12 participates as a cofactor—the conversion of methylmalonyl CoA to succinyl CoA catalyzed by the enzyme methylmalonyl CoA mutase. PP genotype was also associated with a higher percentage of total B12

Table 1. Characteristics of study sample by transcobalamin II genotype

	Transcobalamin II genotype		
	PP	PR	RR
N	39	63	26
Sex (men/women)	33/6	54/9	21/5
Age (y)	66 (\pm 11)	67 (\pm 11)	67 (\pm 11)
B12 (pg/mL)	433 (\pm 177)	415 (\pm 168)	383 (\pm 191)
HoloTCII (pg/mL)	150 (\pm 81)	113 (\pm 56)*	104 (\pm 83)*
% Total B12 on TCII†	34.3 (\pm 9.5)	27.8 (\pm 9.9)*	24.6 (\pm 10.1)*
Methylmalonic acid (nM)	208 (\pm 96)	206 (\pm 80)	264 (\pm 138)‡
Homocysteine (μ M)	10.3 (\pm 2.6)	10.7 (\pm 2.4)	11.2 (\pm 2.8)
RBC folate (ng/mL)	363 (\pm 97)	378 (\pm 106)	398 (\pm 106)
Creatinine (mg/dL)	1.1 (\pm 0.9)	1.1 (\pm 1.0)	1.1 (\pm 0.6)
Hematocrit (%)	43.4 (\pm 3.2)	43.8 (\pm 3.5)	43.6 (\pm 3.3)
MCV (μ m ³)	93.9 (\pm 3.2)	92.9 (\pm 3.2)	92.2 (\pm 5.1)

Values represent means (\pm SD).

†Calculated using the equation: $100 \times (\text{holoTCII}/\text{total B12})$.

*Significantly less than PP genotype after controlling for potential confounding by age, sex, and total B12 ($P \leq .006$).

‡Significantly greater than PP and PR genotypes after controlling for potential confounding by age, sex, total B12, and creatinine ($P \leq .02$).

bound to TC compared with the other genotypes. This suggests that the PP genotype has higher affinity for B12 than the RR genotype, but remains to be definitively determined.

No differences in mean homocysteine concentrations were observed among the genotypes. This is in contrast to a previous finding that the PR genotype is associated with higher homocysteine than either homozygous genotype,^{8,11} a finding unconfirmed in 2 other reports.^{9,10} It has been suggested that the discrepancy between the studies with respect to homocysteine levels is related to differences in the age of the study subjects, with younger subjects exhibiting the homocysteine difference and older subjects not.¹¹ A more likely explanation is that the higher homocysteine observed in PR subjects in one study¹¹ was related to some other uncontrolled determinant of homocysteine, such as sex, B vitamin levels (folate, B12, B6), kidney function, thyroid function, and other genetic factors.¹⁸ In this regard, methylmalonic acid may be better than homocysteine as an indicator of the effect of TCII genotype on functional B12 status because methylmalonic acid is influenced by fewer confounding factors. Notably, in the present study, significant differences in methylmalonic acid among the genotypes were observed after controlling for age, sex, serum creatinine and total B12 level.

We conclude that the TCII 775G>C genotype significantly influences tissue B12 delivery and functional B12 status. Because none of the subjects in the study sample exhibited evidence of hematologic abnormalities, the differences among the genotypes in methylmalonic acid and holoTCII may represent preclinical alterations in B12 status and function. It remains to be determined whether TCII genotype ultimately influences the susceptibility of persons to develop the overt clinical manifestations of B12 deficiency, including hematologic and neurologic sequelae.

Acknowledgments

We thank Genevieve Hill for coordinating subject participation and Wally Thomas for supervision of phlebotomy and blood processing (University of Missouri, Columbia). We thank Lisa M. Rogers, Rebecca F. Cotterman, and Autumn Nguyen for conducting methylmalonic acid and holoTCII assays and Angela Devlin for assistance in developing the TCII genotyping assay (University of California, Davis).




Figure 1. Representative gel illustrating PCR and MvaI digestion products indicative of the 3 775G>C TCII genotypes. PCR products measured 218 bp. Complete digestion of the PCR product with MvaI led to 2 fragments measuring 128 and 90 bp. Complete digestion of the PCR product (2 bands) was indicative of the PP genotype (sample 1), partial digestion (3 bands) was indicative of the PR genotype (sample 2), and no digestion (1 band) was indicative of the RR genotype (sample 3).

References

- Daiger SP, Labowe ML, Parsons M, Wang L, Cavelli-Sforza LL. Detection of genetic variation with radioactive ligands, III: genetic polymorphism of transcobalamin II in human plasma. *Am J Hum Genet.* 1978;30:202-214.
- Frater-Schroder M, Hitzig WH, Butler R. Studies on transcobalamin (TC), I: detection of TC II isoproteins in human serum. *Blood.* 1979;53:193-203.
- Hansen M, Frater-Schroder M. Human transcobalamin isopeptides: separation by isoelectric focusing and by polyacrylamide gel electrophoresis. *Electrophoresis.* 1987;8:221-223.
- Platica O, Janeczko R, Quadros EV, Regec A, Romain R, Rothenberg SP. The cDNA sequence and the deduced amino acid sequence of human transcobalamin II show homology with rat intrinsic factor and human transcobalamin I. *J Biol Chem.* 1991;266:7860-7863.
- Li N, Seetharam S, Lindemans J, Alpers DH, Arwert F, Seetharam B. Isolation and sequence analysis of variant forms of human transcobalamin II. *Biochim Biophys Acta.* 1993;1172:21-30.
- Li N, Sood GK, Seetharam S, Seetharam B. Polymorphism of human transcobalamin II: substitution of proline and/or glutamine residues by arginine. *Biochim Biophys Acta.* 1994;1219:515-520.
- Namour F, Guy M, Aimone-Gastin I, de Nonancourt M, Mrabet N, Guéant J-L. Isoelectric phenotype and relative concentration of transcobalamin II isoproteins related to the codon 259 Arg/Pro polymorphism. *Biochem Biophys Res Comm.* 1998;251:769-774.
- Namour F, Olivier J-L, Abdelmoutaleb I, et al. Transcobalamin codon 259 polymorphism in HT-29 and Caco-2 cells and in Caucasians: relation to transcobalamin and homocysteine concentration in blood. *Blood.* 2001;97:1092-1098.
- Afman LA, Van Der Put NMJ, Thomas CMG, Trijbels JMF, Blom HJ. Reduced vitamin B12 binding by transcobalamin II increases risk of neural tube defects. *Q J Med.* 2001;94:159-166.
- McCaddon A, Blennow K, Hudson P, Regland B, Hill D. Transcobalamin polymorphism and homocysteine. *Blood.* 2001;98:3497-3499.
- Namour F, Guéant J-L. Transcobalamin polymorphism, homocysteine, and aging. *Blood.* 2001;98:3499.
- Flynn MA, Nolph GB, Baker AS, Krause G. Aging in humans: a continuous 20-year study of physiological and dietary parameters. *J Am Coll Nutr.* 1992;11:660-672.
- Rasmussen K. Solid-phase sample extraction for rapid determination of methylmalonic acid in serum and urine by a stable-isotope-dilution method. *Clin Chem.* 1989;35:260-264.
- Gilfix BM, Blank DW, Rosenblatt DS. Novel reductant for determination of total plasma homocysteine. *Clin Chem.* 1997;43:687-688.
- Goh YT, Jacobsen DW, Green R. Diagnosis of functional cobalamin deficiency: utility of transcobalamin-bound vitamin B12 determination in conjunction with total serum homocysteine and methylmalonic acid [abstract]. *Blood.* 1991;78:100.
- Jacobsen DW, Huennekens FM. Purification of B12-binding proteins using a photodissociative affinity matrix. *Methods Enzymol.* 1986;123:28-36.
- Pezacka EH, Jacobsen DW, Luce K, Green R. Glial cells as a model for the role of cobalamin in the nervous system: impaired synthesis of cobalamin coenzymes in cultured human astrocytes following short-term cobalamin deprivation. *Biochem Biophys Res Commun.* 1992;184:832-839.
- Nygaard O, Vollset SE, Refsum H, Brattstrom L, Ueland PM. Total homocysteine and cardiovascular disease. *J Intern Med.* 1999;246:425-454.